Does cDNA stock pay dividends?
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California. More... CDNA does not currently pay a dividend.
Who buys caredx (cDNA)?
CDNA stock was purchased by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Exchange Traded Concepts LLC, Foundations Investment Advisors LLC, and Lindbrook Capital LLC. View insider buying and selling activity for CareDx or or view top insider-buying stocks.
How much of caredx's stock are insiders selling?
In the past three months, CareDx insiders have sold 604.55% more of their company's stock than they have bought. Specifically, they have bought $211,700.00 in company stock and sold $1,491,540.00 in company stock. Only 4.60% of the stock of CareDx is held by insiders.
See more
Is Cdna stock a good buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: CDNA) stock is to Strong Buy CDNA stock.
Is CareDx a good stock to buy?
CareDx's analyst rating consensus is a 'Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
Who owns CareDx?
Peter Maag, PhD Maag has served as CareDx President and CEO, Chairman and CEO or Executive Chairman since October 2012 until November 2021, and has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Peter was President of Novartis Diagnostics.
How many employees does CareDx have?
It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California....Compare CDNA With Other Stocks.CareDx Annual Number of Employees20204752019386201823120171796 more rows
Who is the CEO of CareDx?
Reginald Seeto (Nov 1, 2020–)CareDx / CEO
When did CareDx launch AlloSure?
In post-transplant diagnostics, we offer AlloMap®, which is a heart transplant molecular test, and in October 2017 we launched AlloSure®, which is a donor-derived cell free DNA, or “dd-cfDNA” test initially used for kidney transplant patients.
Recently Viewed Tickers
CareDx Inc
Visit a quote page and your recently viewed tickers will be displayed here.
60 Biggest Movers From Yesterday
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
Tesla's Elon Musk Cuts Law Firm After It Won't Fire Lawyer in SEC Probe, Report Says
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
McDonald's Takes on KFC, Wendy's With a Spicy New Menu Item
A Tesla lawyer asked law firm Cooley to fire an attorney who worked on a U.S. Securities and Exchange Commission investigation of Elon Musk, according to a Wall Street Journal report.
Upcoming Tech SPAC Helps Checkers Jump McDonald's
The fast-food chain has been testing a garlic pepper spicy chicken nugget, but there's a catch.
Lucid's 2030 EV Production Goals Bring It to Half Where Tesla Stands Now
Checkers and Rally's restaurants will deploy Presto's automated voice ordering system at company-owned drive-thru locations in 2022.
DirecTV Drops Far-Right Channel OAN News
The electric vehicle company has a production plan that shows just how speculative its nearly $70 billion valuation is.
Royal Caribbean, Norwegian Cancel More Cruises: Why That's Not Bad for Investors
The move may set off a backlash against the satellite-TV company in which AT&T holds a 70% stake.
Crocs Files For NFT Trademark
The cruise lines have canceled select sailings but Royal Caribbean and Norwegian Cruise Line shareholders should take that as a positive.
About CareDx
The footwear company filed a trademark application to use its name on future NFTs.
CareDx (NASDAQ:CDNA) Frequently Asked Questions
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.
About CDNA
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CareDx stock. View analyst ratings for CareDx or view top-rated stocks.
Stats
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.
Rating
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
